Northrop Grumman (NOC) Q1 Earnings Preview: Will Margins Finally Recover?

Key Takeaways

• Consensus estimates call for Q1 EPS of $6.05 with revenue reaching $9.76 billion, representing 3.1% annual growth
• The analyst community maintains a Buy rating with an average price target of $736.24, suggesting approximately 11% potential appreciation from current levels near $665
• Profitability improvement remains paramount, with segment operating margins projected to reach roughly 11%
• Latest awards feature a $475M Glide Phase Interceptor contract adjustment and successful YFQ-48A Talon Blue drone engine testing
• Shares have declined 2% in the past 30 days while the aerospace and defense industry has surged 10.3%

Northrop Grumman delivers its first-quarter 2026 financial results on Tuesday morning. Following an extended period of substantial R&D investments, market participants are laser-focused on a single question: are profitability metrics truly beginning to improve?

Northrop Grumman Corporation, NOC

The Street anticipates earnings per share of $6.05 alongside revenue of $9.76 billion. While these figures represent a sequential decline from Q4’s $7.23 EPS and $11.7 billion sales, this pattern is characteristic of the industry. Defense industry participants consistently deliver peak performance in the fourth quarter.

Compared to the prior-year period, topline growth is projected at 3.1%. This would mark a significant turnaround from the 6.6% revenue contraction Northrop experienced in last year’s opening quarter.

During the previous reporting period, the company exceeded expectations on both revenue and operating performance. Sales totaled $11.71 billion, climbing 9.6% annually. Earnings per share reached $7.23, surpassing the $6.99 Street estimate. The primary disappointment centered on full-year earnings guidance, which fell short of analyst projections.

Shares currently trade in the $665–$667 range, positioned near the midpoint of the 52-week trading band spanning $450.13 to $774.00. Sell-side price objectives have demonstrated upward momentum. Wells Fargo launched coverage with a Buy recommendation and $800 target on March 31. Deutsche Bank elevated its target to $778 on April 8. Jefferies adjusted its Hold-rated objective upward to $710 on April 9.

Earnings projections have increased 0.51% during the past two months. Revenue forecasts have risen 0.24%. While incremental, the trend points in a favorable direction.

Profitability Metrics Under the Microscope

The primary issue confronting investors ahead of Tuesday’s announcement centers on whether margin expansion is materializing in reported figures. The analytical community projects segment operating margins will recover to approximately 11%.

The Aeronautics division is cycling past a B-21 Raider development expense from the comparable period, which should provide a tailwind. Mission Systems stands to gain from an enhanced program portfolio. Should both divisions perform as anticipated, it would indicate that Northrop’s capital-intensive development cycle is genuinely reaching an inflection point.

Full-year earnings guidance also commands attention. Current guidance spans $27.40 to $27.90. Market watchers expect leadership to maintain this range, although some believe the more compelling growth narrative unfolds in 2027.

New Contract Awards Build Momentum

Northrop has experienced an active April regarding program wins. The defense prime secured a $475 million contract modification to expedite Glide Phase Interceptor development. Its YFQ-48A Talon Blue autonomous combat platform successfully completed initial engine testing on April 17. The Sentinel intercontinental ballistic missile program continues progressing toward an inaugural flight in 2027.

NOC shares have retreated approximately 2% during the trailing month. The broader aerospace and defense industry has advanced 10.3% over the identical timeframe, positioning Northrop among the sector’s laggards entering the earnings release.

Industry peers have already begun their reporting cycle. AAR delivered 24.6% revenue expansion and exceeded forecasts, with shares rallying 9.9%. Byrna achieved 10.9% growth but missed expectations, tumbling 38.3%.

Analysts have maintained relatively stable estimates throughout the past 30 days, implying limited anticipation of significant deviations in either direction.